Venmax Drugs and Pharmaceuticals Limited (BOM:531015)

BOM:531015 Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-0.11	0.65	2.26	18.46	-1.62
Depreciation & Amortization	0.06	0.07	0.08	0.09	0.1
Other Operating Activities	-0.04	-0	0	0	0.01
Change in Accounts Receivable	-9.53	0.36	-	-0	0.02
Change in Inventory	-0.58	-	-	-	2.16
Change in Accounts Payable	5.25	-2.25	-1.42	0.06	0.63
Change in Other Net Operating Assets	-17.98	1.19	-0.95	0.44	1.35
Operating Cash Flow	-22.9	0.02	-0.03	19.05	2.64
Operating Cash Flow Growth	-	-	-	621.97%	-
Short-Term Debt Issued	-	-	0.03	-	-
Total Debt Issued	-	-	0.03	-	-
Short-Term Debt Repaid	-	-	-	-19.8	-1.9
Long-Term Debt Repaid	-3.03	-	-	-	-
Total Debt Repaid	-3.03	-	-	-19.8	-1.9
Net Debt Issued (Repaid)	-3.03	-	0.03	-19.8	-1.9
Other Financing Activities	50.73	-	-	-	-
Financing Cash Flow	47.7	-	0.03	-19.8	-1.9
Miscellaneous Cash Flow Adjustments	-	-	-	-0	-
Net Cash Flow	24.8	0.02	-	-0.75	0.74
Free Cash Flow	-22.9	0.02	-0.03	19.05	2.64
Free Cash Flow Growth	-	-	-	621.97%	-
Free Cash Flow Margin	-283.69%	-	-	-	157.18%
Free Cash Flow Per Share	-4.36	0.00	-0.01	3.64	0.50
Cash Income Tax Paid	-	0.23	-	-	-
Levered Free Cash Flow	-29.62	-1.32	-3.5	-0.27	3.25
Unlevered Free Cash Flow	-29.62	-1.32	-3.5	-0.27	3.25
Change in Net Working Capital	23.01	0.69	2.37	-0.49	-4.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.